Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19

ClinicalTrials.gov ID: NCT04425629

Public ClinicalTrials.gov record NCT04425629. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 12:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Phase 1 * To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo * To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2 Phase 2 • To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2 Phase 3 * Cohort 1 (≥18 Years Old, Not Pregnant at Randomization) • To evaluate the clinical efficacy of REGN10933+REGN10987 compared to placebo as measured by COVID-19-related hospitalizations or all-cause death * Cohort 2 (\<18 Years Old, Not Pregnant at Randomization) * To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo * To further characterize the concentrations of REGN10933 and REGN10987 in serum over time * Cohort 3 (Pregnant at Randomization) • To evaluate the safety and tolerability of REGN10933+REGN10987

Study identification

NCT ID
NCT04425629
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
10,078 participants

Conditions and interventions

Eligibility (public fields only)

Age range
Not listed
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 15, 2020
Primary completion
Jan 20, 2022
Completion
Jun 8, 2022
Last update posted
Dec 20, 2023

2020 – 2022

United States locations

U.S. sites
102
U.S. states
27
U.S. cities
74
Facility City State ZIP Site status
Regeneron Study Site Mesa Arizona 85210
Regeneron Study Site Tucson Arizona 85712
Regeneron Study Site Tucson Arizona 85724
Regeneron Study Site Canoga Park California 91303
Regeneron Study Site La Mesa California 91942
Regeneron Study Site La Palma California 90623
Regeneron Study Site 1 Long Beach California 90806
Regeneron Study Site 2 Long Beach California 90806
Regeneron Study Site 3 Long Beach California 90806
Regeneron Study Site Los Angeles California 90036
Regeneron Study Site Montclair California 91763
Regeneron Study Site Rolling Hills Estates California 90274
Regeneron Study Site Sacramento California 95817
Regeneron Study Site San Francisco California 94127
Regeneron Study Site Santa Monica California 90404
Regeneron Study Site Stanford California 94305
Regeneron Study Site Aurora Colorado 80045
Regeneron Study Site Colorado Springs Colorado 80907
Regeneron Study Site Washington D.C. District of Columbia 20037
Regeneron Study Site Boca Raton Florida 33487
Regeneron Study Site DeLand Florida 32720
Regeneron Study Site Ft. Pierce Florida 34982
Regeneron Study Site Hialeah Florida 33010
Regeneron Study Site Loxahatchee Groves Florida 33470
Regeneron Study Site Maitland Florida 32751
Regeneron Study Site Miami Florida 33012
Regeneron Study Site 1 Miami Florida 33126
Regeneron Study Site 2 Miami Florida 33126
Regeneron Study Site Miami Florida 33130
Regeneron Study Site Miami Florida 33144
Regeneron Study Site Miami Florida 33184
Regeneron Study Site Sarasota Florida 34239
Regeneron Study Site St. Petersburg Florida 33705
Regeneron Study Site Tampa Florida 33606
Regeneron Study Site West Palm Beach Florida 33407
Regeneron Study Site Winter Haven Florida 33880
Regeneron Study Site Winter Park Florida 32789
Regeneron Study Site Atlanta Georgia 30309
Regeneron Study Site Atlanta Georgia 30322
Regeneron Study Site Augusta Georgia 30912
Regeneron Study Site Columbus Georgia 31904
Regeneron Study Site Marietta Georgia 30060
Regeneron Study Site Chicago Illinois 60607
Regeneron Study Site 1 Downers Grove Illinois 60515
Regeneron Study Site 2 Downers Grove Illinois 60515
Regeneron Study Site Downers Grove Illinois 60515
Regeneron Study Site Ames Iowa 50010-3014
Regeneron Study Site Iowa City Iowa 52242
Regeneron Study Site Lake Charles Louisiana 70601
Regeneron Study Site Marrero Louisiana 70072
Regeneron Study Site New Orleans Louisiana 70114
Regeneron Study Site Shreveport Louisiana 71118
Regeneron Study Site Baltimore Maryland 21201
Regeneron Study Site Royal Oak Michigan 48073
Regeneron Study Site Jackson Mississippi 39216
Regeneron Study Site Las Vegas Nevada 89109
Regeneron Study Site Ridgewood New Jersey 07450
Regeneron Study Site Teaneck New Jersey 07666
Regeneron Study Site Santa Fe New Mexico 87505
Regeneron Study Site Jamaica New York 11432
Regeneron Study Site New York New York 10003
Regeneron Study Site New York New York 10019
Regeneron Study Site New York New York 10025
Regeneron Study Site New York New York 10029
Regeneron Study Site New York New York 10032
Regeneron Study Site New York New York 10037
Regeneron Study Site The Bronx New York 10451
Regeneron Study Site The Bronx New York 10461
Regeneron Study Site Charlotte North Carolina 28209
Regeneron Study Site Durham North Carolina 27710
Regeneron Study Site Wilmington North Carolina 28401
Regeneron Study Site Columbus Ohio 43215
Regeneron Study Site Dayton Ohio 45409
Regeneron Study Site Dayton Ohio 45432
Regeneron Study Site Philadelphia Pennsylvania 19140
Regeneron Study Site Providence Rhode Island 02903
Regeneron Study Site Charleston South Carolina 29425
Regeneron Study Site Clinton South Carolina 29325
Regeneron Study Site Sioux Falls South Dakota 57108
Regeneron Study Site 2 Memphis Tennessee 38103
Regeneron Study Site Memphis Tennessee 38103
Regeneron Study Site Amarillo Texas 79109
Regeneron Study Site Corpus Christi Texas 78413
Regeneron Study Site Dallas Texas 75246
Regeneron Study Site Dallas Texas 75390
Regeneron Study Site Houston Texas 77004
Regeneron Study Site Houston Texas 77008
Regeneron Study Site Houston Texas 77030
Regeneron Study Site Houston Texas 77055
Regeneron Study Site Houston Texas 77057
Regeneron Study Site Houston Texas 77093
Regeneron Study Site Pearland Texas 77584
Regeneron Study Site Red Oak Texas 75154
Regeneron Study Site San Antonio Texas 78215
Regeneron Study Site San Antonio Texas 78217
Regeneron Study Site San Antonio Texas 78249
Regeneron Study Site Tyler Texas 75708
Regeneron Study Site Falls Church Virginia 22042
Regeneron Study Site Everett Washington 98201
Regeneron Study Site Seattle Washington 98109
Regeneron Study Site Seattle Washington 98122
Regeneron Study Site Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04425629, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 20, 2023 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04425629 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →